TRAXENS
19.9.2018 16:02:11 CEST | Business Wire | Press release
TRAXENS today announced that ERCI Eurail Clusters has named TRAXENS DIGITAL FREIGHT TRAIN, Europe's first Freight Train to use an innovative IoT-based system allowing digitalization of operations, the winner of their « Coup de Cœur » Innovation Award. The prize has been given to the company at the InnoTrans 2018 tradeshow in Berlin.
Initially launched with Fret SNCF, the TRAXENS DIGITAL FREIGHT TRAIN solution is based on smart devices capable of communicating with each other using wireless digital network. TRAXENS solution goes beyond smart wagons to connect the entire train offering new high-value-added services.
Inherited from the Shipping Industry, TRAXENS DIGITAL FREIGHT TRAIN has been designed to work worldwide and manage any type of asset (e.g., Dry or Reefer container, wagon, trailer) which means that rail freight can be connected to the rest of the supplier chain anywhere, to explore and leverage door-to-door multimodal applications.
« This industry recognition is a major milestone for us. We have achieved to design and implement with our partner SNCF Logistics such a solution in a two-year timeframe, which has never been experienced in the industry. We are looking forward to extending the solution worldwide, said Florence Delalande, Rail Business Unit Director at TRAXENS.
Dirk-Ulrich Krüger, Spokesperson of the European Railway Clusters Initiative, comments: « We are thrilled to recognize next-generation innovation in the railway industry, and that’s why TRAXENS has earned this award from ERCI Eurail Clusters. Some of the best solutions, come from these kinds of forward-thinking players who think outside of the box. »
The DIGITAL FREIGHT TRAIN innovation enables the stakeholders of the railway ecosystem to share benefits and costs:
Railway undertakings optimise their wagon fleet and streamline operations.
Shippers geolocate their shipments in real-time anywhere around the world and receive alerts when their shipment arrives at key locations
Wagon keepers can use preventive and predictive maintenance based on hard facts (accurate mileage tracking, information on abnormal shocks, brake and axle monitoring).
Customized services are possible: remote control, door opening, temperature and humidity monitoring.
About ERCI Innovation Awards
The ERCI Innovation Awards recognize companies from ERCI partner clusters that have successfully introduced innovative products or solutions to the market. The prize is initiated by the European Railway Clusters Initiative (ERCI).
The categories of the ERCI Innovation Awards are:
- “Best Large Enterprise”
- “Best SME”
- “Coup de Cœur” special jury prize
The term of the award is annually. Hosting of the award ceremony rotates among the ERCI members. The 2018 awarding ceremony was hosted by the Cluster Transport, Mobility and Logistics Berlin-Brandenburg at InnoTrans 2018 on Wednesday, 19 September 2018.
The awarding ceremony, which took place at the Berlin-Brandenburg joint booth in the CityCube, hall B, on Wednesday, 19 September 2018, was organised by the ERCI partner Cluster Transport, Mobility and Logistics in Berlin and Brandenburg with support from Berlin Partner of Business and Technology. The ERCI Innovation Awards Ceremony took place for the fourth time in 2018:
About ERCI
The European Railway Clusters Initiative was founded in 2010 with the signature of the cooperation treaty on InnoTrans 2010. Member clusters of ERCI are:
- I-Trans competitiveness cluster (Famars, France)
- BTS Rail Saxony (Dresden, Germany)
- Cluster Mobilität, Verkehr und Logistik Berlin-Brandenburg, c/o Berlin Partner for Business and Technology (Berlin, Germany)
- CNA Cluster Bahntechnik Bayern (Nuremberg, Germany)
- DITECFER (Pistoia, Italy)
- Inno-Pro (Karup, Denmark)
- Järnvägsklustret (Västeras, Sweden)
- Logistics in Wallonia (Grace-Hollogne, Belgium)
- The Rail Alliance (Birmingham, UK)
- Railgrup (Barcelona, Spain)
- Southern Railway Cluster (Katowice, Poland)
The 11 partner clusters represent more than 1,000 companies from railway industry from all over Europe. ERCI aims aims to promote innovation and the development of new business opportunities as a means of sustainably bolstering competitiveness within the European railway industry. ERCI fosters collaboration between industry and research, initiates innovation projects and organises B2B meetings and workshops. This also includes the promotion of good visibility and networking at EU level.
Projects with participation of ERCI partner clusters include
-
PERES (Promoting European Rail Excellence outSide EU), an ESCP 4i
partnership under the roof of the European Cluster Collaboration
Platform (ESCP).
More information: http://www.peresinfo.com/ - RECORD (Regions in Europe Coordinate and Optimize innovation and competitiveness policy instruments towards improving the sustainability of transport – study case of SMEs in the railway sector). More information: https://www.interregeurope.eu/record/
About TRAXENS :
TRAXENS delivers the world's most exhaustive, precise and timely information about containers in transit anywhere in the world using breakthrough technology and Big Data techniques. This information provides all stakeholders in multi-modal transport the opportunity to improve costs, optimize investment, and offer premium services.
For more information: www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005029/en/
Contact:
Press Contact: TRAXENS Geraldine Sauniere, Tel: +33-6-95-91-58-99 Director of Communications g.sauniere@traxens.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom